Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DEXTRAN 70 SODIUM CHLORIDE
Baxter Healthcare Limited
6/0.9 %w/v %w/v
Solution for Infusion
1983-04-01
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gentran 70 (Dextran 70 Intravenous Infusion BP 6.0% w/v in Sodium Chloride Intravenous Infusion BP 0.9% w/v). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1000 ml contains: For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for Infusion. A clear, colourless, sterile, aqueous solution for infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dextran 70 is used for early fluid replacement or for plasma volume expansion in the adjunctive treatment of certain types of shock, or in impending shock when whole blood or fluid products are not available, including shock resulting from burns, surgery, haemorrhage or trauma, in which circulating volume deficit is present. It should not replace other forms of therapy known to be of value in the treatment of shock. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DOSAGE The dosage is dependent upon the age, weight and clinical condition of the patient. _Hypovolaemic shock_ The usual dose is 500 ml to 1000 ml initially, followed by 500 ml later if necessary, depending on the individual response. This dose should not be exceeded except in unusual circumstances. Recommended dosage in children is 10 ml/kg and in babies 5ml/kg. ADMINISTRATION The solution is for administration by intravenous infusion only. 4.3 CONTRAINDICATIONS Dextran 70 Intravenous Infusion BP is contraindicated in the presence of thrombocytopenia, severe congestive heart failure, renal disease with severe oliguria or anuria, where there is known hypersensitivity to Dextran, and in patients receiving heparin or low molecular weight heparins (see below). Dextran 70 (Dextran 70 for Injection) 60 g Sodium Chloride 9 g IRISH MEDICINES BOARD ______________________________________________________________ Read the complete document